The FDA this week expanded Johnson and Johnson’s Stelara’s psoriatic arthritis label, expanding its use to pediatric patients aged six and older. Stelara first launched in 2009 as a therapy for moderate to severe plaque psoriasis, and has since expanded across the immunology space. For the treatment of psoriatic arthritis, virtually all insured lives (99%) have covered or better access to Stelara under the pharmacy benefit. About 40% of those lives have preferred access to Stelara, largely with utilization management restrictions applied.
SOURCE: MMIT Analytics, as of 8/3/22